Irritable bowel syndrome is a common chronic gastrointestinal condition characterized by abdominal pain and bloating with altered bowel habits.
There are no identifiable physical, radiologic or lab abnormalities indicative of organic disease.
Symptoms may be exacerbated by stress, alcohol or food.
Delivering percutaneous electrical nerve field stimulation to the external ear via a noninvasive device helps ease abdominal pain and improve overall wellbeing in teens with irritable bowel syndrome (IBS), as shown in a study.
Patients with treatment-refractory irritable bowel syndrome (IBS) with predominant bloating may fare well with faecal microbiota transplantation (FMT), which has been shown in a study to induce symptom relief. However, the beneficial effects wane over 1 year, and a second FMD appears to re-establish the benefits but only in those who have shown a prior response.
A number of psychological therapies help aid in the treatment of irritable bowel syndrome (IBS), with cognitive behavioural therapy (CBT)-based interventions and gut-directed therapy being the most effective over the long term, according to the results of a meta-analysis.
Treatment with minesapride in patients with irritable bowel syndrome with constipation (IBS-C) is well tolerated and helps improve stool frequency, as well as abdominal and overall symptoms, according to the results of a phase II study from Japan.
Treatment with tenapanor 50 mg twice daily (bid) results in improvement of constipation-predominant irritable bowel syndrome (IBS-C) symptoms and is generally well tolerated, a phase III study has shown.
An association appears to exist between irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO), suggest the results of a systematic review and meta-analysis. However, the overall quality of evidence is low.
Stool microbial diversity and composition appear to have a significant effect on daily extraintestinal symptoms, stool consistency and quality of life (QoL) in women with irritable bowel syndrome (IBS), a recent study has shown.
Peppermint oil, regardless of whether it is released in the small intestine or in the ileocolon, is ineffective for overall symptom relief in irritable bowel syndrome (IBS), a new study has found. In contrast, it shows significant efficacy for abdominal pain, discomfort and disease severity.
Faecal microbiota transplantation (FMT) is effective in reducing symptoms of irritable bowel syndrome (IBS), but having a “super-donor” is key, a study presented at UEG* Week has shown — highlighting the importance of donor selection for the success of FMT as a treatment for IBS.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).